Clarence D. Moore, PharmD, BCPS

700 Scott st

Articles

Drugs in Perspective: Zykadia (ceritinib)

October 09, 2014

Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.